



Press Release

ULTRASPECT RECONFIRMS FDA-CLEARED DOSE-REDUCTION SOLUTION TO THE TECHNETIUM SHORTAGE

UltraSPECT Offers Three Alternative Solutions for Dose-Reduction Imaging in Nuclear Cardiology with No Trade-Off in Imaging Time and Image Quality

Auburndale, Massachusetts, February 2, 2010 —UltraSPECT, a leading provider of Nuclear Medicine image reconstruction products for enhancing the performance of gamma cameras by shortening acquisition times, enabling reduced radiopharmaceutical doses and increasing image resolution, announced today three different clinically proven protocols for reduced-dose cardiac imaging, requiring absolutely no compromise in terms of image quality or longer scan times. These imaging protocols minimize radiation exposure to patients and staff in addition to mitigating the impact of the Technetium shortage on the practice. They are made possible, thanks to UltraSPECT's proprietary WBR™ image reconstruction capabilities available on the Xpress.Cardiac™ and the Xpert3.Cardiac™ products.

Due to the impact of the Canadian reactor shutdown combined with the recently announced closure due to the six-month repair plan of the Netherlands reactor, the global shortage of Tc-99m is expected to remain grave for the period covering February-August 2010, leaving the field of Nuclear Medicine in a very precarious position:

- Inability to provide patients with needed Nuclear Medicine tests
- Longer delays in scheduling of exams for most patients
- Use of non-validated reduced-dose imaging protocols with risk of inadequate clinical outcomes
- Loss of business to other imaging modalities such as CTA, Echo and cardiac PET

UltraSPECT's clinically proven imaging alternatives using the FDA-cleared and CE mark-approved Xpress.Cardiac and Xpress3.Cardiac products help weather this period; the products allow the utilization of lower dose imaging protocols with no compromise in imaging acquisition times and outcomes, alleviating the impact of the Technetium shortage, while at the same time reducing patient radiation exposure. UltraSPECT products feature connectivity to the imaging systems of all three major NM camera manufacturers, supporting most existing camera hardware and workstation versions.

With the Xpress.Cardiac you can apply the one-day Rest/Stress protocol, with scan times as defined by the ASNC recommendations, but with injected doses that are approximately half the doses specified by ASNC:

Rest: 5-6 mCi; 8-9 mCi for patients weighing >100 kg.

Stress: 15-20 mCi; 24-27 mCi for patients weighing >100 kg.

With the Xpress3.Cardiac you can apply 2 different protocols: the "half-dose, half-time" single-day Rest/Stress protocol or the dual-isotope single-day protocol.

As suggested by its name, the half-dose, half-time protocol combines reduced injection doses with shortened scan times, enabling higher patient safety and comfort, while helping overcome the impact of radioisotope supply shortages and increasing patient throughput. A typical "half-dose half-time" same-day Tc-99m Rest/Stress protocol consists of:

Rest: 5-6 mCi; 15-20 sec. per stop.



Stress: 15-20 mCi; 10 sec per stop.

The one-day dual-isotope Tl-201/Tc-99m protocol combines reduced doses and shorter scan times. Reduced-dose shorter-time Rest Tl-201 imaging is followed by shorter-time reduced-dose Tc-99m Stress imaging:

Rest: Tl-201, 2 mCi (female) / 3 mCi (male); 20sec. per stop.

Stress: Tc-99m, 20 mCi (female) / 30 mCi (male); 10sec. per stop.

Many users of the dose-reduction protocols enabled by UltraSPECT's image reconstruction products attest that they have not been impacted by the reactor shutdowns due to the more effective utilization of their limited Technetium supplies. "WBR technology has been instrumental in maintaining our high patient throughput throughout the Technetium shortage. With half-dose imaging performed on nearly one thousand patients in our clinic, we have managed to minimize the effect of the reduced supply," said James Reibsane, CNMT, Director of Diagnostic and Technical Services at Berks Cardiologists Ltd., Wyomissing, PA.

UltraSPECT's Xpress.Cardiac, Xpress3.Cardiac, and Xpress/Xact.Bone™ products are distributed in the USA exclusively by Cardinal Health.

About UltraSPECT

UltraSPECT Ltd., based in Haifa, Israel, with U.S. offices in Auburndale, MA, is a leading provider of products dedicated to enhancing the performance of Nuclear Medicine gamma cameras by shortening acquisition times, increasing image resolution, and providing the potential for reduced radiopharmaceutical doses. Compatible with most major manufacturers' cameras and workstations, these products can be installed within hours, offering a transparent interface between the camera and workstation. Shorter acquisitions improve patient comfort, reducing patient motion, and increase patient throughput without compromising image quality. Higher resolution offers improved lesion localization, raising diagnostic confidence. Lower doses reduce patient exposure to radiation. Xpress.Cardiac and Xpress3.Cardiac cut cardiac imaging times to one-half and one-quarter, respectively, without compromising image quality; Xpress/Xact.Bone can either cut bone imaging acquisition times by half, or double the image resolution. UltraSPECT products are distributed in the USA by Cardinal Health (www.cardinalhealth.com).

For more information visit our website: www.ultraspect.com, or contact UltraSPECT Inc. at 1(888) WBR-SCAN (1-888-927-7226).